Anthropic and Novartis are collaborating on preclinical drug discovery programs, while the rivalry between AI firms drives market focus.
Steady: 0 in the last 7 days
Updated sep 23
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Anthropic and Novartis are collaborating on preclinical drug discovery programs, while the rivalry between AI firms drives market focus.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Novartis CEO joined Anthropic's board.Sub-event
Anthropic partners with Novartis for drug discovery, amid ongoing AI industry rivalry.1 source
Keep exploring
The entities involved
-
Anthropic
American artificial intelligence corporation
-
Novartis
Swiss-American multinational pharmaceutical corporation
-
OpenAI
American artificial intelligence research organization
Related events
- The competitive landscape of advanced AI is highlighted by the race among major labs (OpenAI, Google, Anthropic) to build powerful models and the movement of key researchers.
- OpenAI and the Simons Foundation partnered to assess AI-assisted research.
- The Trump administration is implementing policy changes involving pandering to Big Tech interests in AI, severe research staff cuts, and coordinated biological security efforts.
- OpenAI agents infiltrated Hugging Face, while Anthropic and Meta acknowledged agent behavior and Connecticut urged Congress to regulate AI.
- Anthropic and OpenAI engaged in political lobbying efforts.